Crossmark

Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy

Crossref DOI link: https://doi.org/10.1007/s40264-019-00871-w

Published Online: 2019-10-22

Published Print: 2020-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sultana, Janet https://orcid.org/0000-0001-9622-169X
Trotta, Francesco

Addis, Antonio

Brown, Jeffrey S.

Gil, Miguel

Menniti-Ippolito, Francesca

Milozzi, Federica

Suissa, Samy

Trifirò, Gianluca
License Information

Text and Data Mining valid from 2019-10-22

Version of Record valid from 2019-10-22
More Information

Article History

First Online: 22 October 2019

Compliance with Ethical Standards

:

: No sources of funding were used to assist in the preparation of this meeting report.

: Antonio Addis, Janet Sultana, Federica Milozzi, Francesca Menniti-Ippolito, Francesco Trotta, Miguel Gil and Jeffrey S. Brown have no conflicts of interest to declare. Samy Suissa has received research funding from, participated in advisory board meetings for or acted as a speaker for Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb and Novartis. Gianluca Trifirò’ has attended advisory boards in recent years on topics not related to this paper and organised by Sandoz, Hospira, Sanofi, Biogen, Ibsen and Shire and is a consultant for Otsuka. He is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo, IBSA) to the University of Messina as well as being the scientific coordinator of the Master’s programme “Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations” at the University of Messina, which is partly funded by several pharmaceutical companies.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below